Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Alnylam Eyes RNAi for Manufacturing Drugs
|
Ryan McBride |
11/12/09 |
Boston
|
|
Alnylam Chief Foresees Another Gene-Silencing Spin-Off, and More News Tidbits from Boston’s MassBio Investors Forum
|
Ryan McBride |
10/07/09 |
Boston
|
|
Alnylam and Tekmira Seek New Ways to Deliver RNAi Drugs Deep in the Body
|
Ryan McBride |
08/06/09 |
Boston
|
|
Replacing Phil Sharp Will Be Up to Biogen’s Board
|
Ryan McBride |
07/20/09 |
Boston
|
|
Novartis Extends Alnylam Deal
|
Ryan McBride |
07/17/09 |
Boston
|
|
Isis, Alnylam to Collaborate on Single-Stranded RNA Drugs; Deal Could Add Up to $31 Million to Isis’ Coffers
|
Wade Roush |
04/29/09 |
San Diego
|
|
Cleaner Water Through Biotech? 349Q Kills Water-Borne Microbes with RNAi
|
Wade Roush |
04/27/09 |
Boston
|
|
Alnylam to Receive European Patent
|
Ryan McBride |
04/20/09 |
Boston
|
|
Traversa Gets $5M
|
Juha-Pekka Tikka |
04/02/09 |
San Diego
|
|
Intellectual Ventures Inks India Deal, Ontela Teams with T-Mobile, MDRNA Nabs $7.25M, & More Seattle-Area Deals News
|
Gregory T. Huang |
03/24/09 |
Seattle
|
|
Aura Biosciences Aims to Develop “Ballistic Missile” Drug to Beat Pancreatic Cancer, Deliver RNAi Therapies
|
Ryan McBride |
03/12/09 |
Boston
|
|
Regulus Therapeutics Follows Through on Fundraising, Independence Plans
|
Ryan McBride |
03/04/09 |
San Diego
|
|
RXi to Sell up to $25M in Stock
|
Ryan McBride |
02/05/09 |
Boston
|
|
Alnylam, Cubist Will Cooperate on RNAi Drug for Lung Infections
|
Wade Roush |
01/09/09 |
Boston
|
|
Another Next-Generation RNAi Startup Emerges, Makes Big Claims About Its Ability to Silence Bad Genes
|
Ryan McBride |
12/18/08 |
Boston
|
|
Mass Life Sciences Center Attracts J&J Matching Funds, Awards $3.7M in Industry-Academic Grants
|
Ryan McBride |
12/16/08 |
Boston
|
|
Alnylam Forms UCSF Collaboration
|
Ryan McBride |
12/11/08 |
Boston
|
|
Alnylam Buys More RNAi Patents From Nucleonics
|
Luke Timmerman |
12/08/08 |
Boston
|
|
Aileron Develops New Class of Drugs To Go Where None Could Before
|
Luke Timmerman |
11/07/08 |
Boston
|
|
Alnylam Hires Chief Scientist, Jack Schmidt, To Help Build RNAi Pipeline
|
Luke Timmerman |
10/01/08 |
Boston
|
|
Alnylam Sees Opportunity in Turning Genes On, And Off
|
Luke Timmerman |
09/05/08 |
Boston
|
|
Hub’s Slice of J&J’s R&D Investment Pie—New Funds from the Medical-Products Giant for Harvard and CIMIT
|
Ryan McBride |
08/18/08 |
Boston
|
|
Alnylam, Novartis Extend RNA Interference Collaboration
|
Luke Timmerman |
07/16/08 |
Boston
|
|
Alnylam Loses RNAi Patent in Europe; Analyst Says No Worries
|
Luke Timmerman |
07/11/08 |
Boston
|
|
RXi Plans $8.7M Stock Sale
|
Rebecca Zacks |
06/24/08 |
Boston
|
|
Alnylam Inks $93M Japanese Deal
|
Rebecca Zacks |
06/19/08 |
Boston
|
|
Alnylam Invests $5M in Canadian RNAi Company
|
Luke Timmerman |
06/02/08 |
Boston
|
|
Novartis Increases Stake in Alnylam
|
Wade Roush |
05/08/08 |
Boston
|
|
Alnylam Joint Venture Regulus Inks Deal with GSK Worth up to $600 Million
|
Erik Mellgren |
04/17/08 |
Boston
|
|
Mello RNAi Firm RXi Pharmaceuticals Has Wild Ride on First Day of Trading
|
Rebecca Zacks |
03/12/08 |
Boston
|
|
Page 1 of
2 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
